Biogen (BIIB) Gross Profit (2009 - 2026)

Biogen's Gross Profit history runs 18 years deep, the most recent figure standing at $2.0 billion for Q2 2026.

• In Q2 2026, Gross Profit fell 3.99% year-over-year to $2.0 billion; the TTM figure through Jun 2026 stood at $7.4 billion (down 1.6% YoY), while the FY2025 annual figure was $7.5 billion, up 1.64% from the prior year.
• Gross Profit for Q2 2026 stood at $2.0 billion, up from $1.8 billion in the prior quarter.
• The five-year high for Gross Profit was $2.4 billion in Q4 2022, with the low at $1.7 billion in Q1 2024.
• The 5-year median for Gross Profit is $1.9 billion (2023), against an average of $2.0 billion.
• The sharpest annual moves came in 2023 and 2025: Gross Profit retreated 20.23% in 2023, then climbed 6.34% in 2025.
• Biogen's Gross Profit stood at $2.4 billion in 2022, then dropped by 6.63% to $2.2 billion in 2023, then dropped by 15.8% to $1.9 billion in 2024, then slipped by 4.67% to $1.8 billion in 2025, then advanced by 9.82% to $2.0 billion in 2026.
• Business Quant data shows BIIB's Gross Profit at $2.0 billion in Q2 2026, $1.8 billion in Q1 2026, and $1.8 billion in Q4 2025.